You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A BioPhysical Approach to Resuscitation Fluids

    SBC: BIOPHYZICA, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Circulatory, hypoxemic or traumatic arrest claims an estimated 350,000 lives per year in the United States accounting for almost 15% of all deaths. Circulatory, hypoxemic, or traumatic arrests result in whole-body ischemia, most significantly global cerebral ischemia. Brain cells die when they no longer receive oxygen and nutrients from the blood. Because cereb ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  2. Acne Vaccines Targeting a Surface Sialidase and a Secreted CAMP Factor Toxin

    SBC: VAXIN INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Propionibacterium acnes (P. acnes) is most notably recognized for its role in acne vulgaris, the most common skin disease, affecting 85-100% of the population at some point in their lives. Current treatments for vulgari s acne using isotretinoin (13-cis-retinoic acid) or antibiotics can have many undesirable effects, including depression, teratogenicity, hormon ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  3. Acute-infarct selective cardiac MRI contrast agent

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Reliable diagnostic differentiation between acute and chronic myocardial infarcts would be of great benefit for cardiac surgeons and interventional cardiologists. Such differentiation could be used to make decisions about which vessels and in what order would be reopened or bypassed. MRI is an intrinsically noninvasive diagnostic tool and the Delayed Enhancemen ...

    STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health
  4. Acute-infarct selective cardiac MRI contrast agent

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Adenovirus vectored vaccines for Alzheimer's disease

    SBC: VAXIN INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Alzheimer disease (AD) is the most common neurodegenerative disease in the elderly. To date, no satisfactory treatment is available for AD. One of the pathological hallmarks of AD is deposits of amyloid protein (Aa) in neuritic plaques and cerebral vessels. Increasing lines of evidence support the notion that Aa and its precursor (APP) play pathogenetic roles i ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  6. A device containing an immobilized chelator to remove aluminum from total parente

    SBC: ALKYMOS, INC            Topic: NICHD

    DESCRIPTION (provided by applicant): A high percentage of the ~ 500,000 children born prematurely each year in the US require intravenous feeding after birth because they do not tolerate oral feeding. This is accomplished with a total parenteral nutrition (TPN) solution, which is prepared from component solutions: small and large volume parenterals (SVPs and LVPs). Aluminum (Al) is a common contam ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  7. A device containing immobilized chelator to remove aluminum from TPN solutions

    SBC: ALKYMOS, INC            Topic: N/A

    DESCRIPTION (provided by applicant): A high percentage of the ~ 470,000 children born prematurely each year in the US require intravenous feeding after birth because they do not tolerate oral feeding. This is accomplished with a total parenteral nutrition (TPN) solution, which is prepared from component solutions: small and large volume parenterals (SVPs and LVPs). Aluminum (Al) is a common conta ...

    STTR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health
  8. A 3-D Robot Design to Overcome Arm Dysfunction in Stroke

    SBC: LAM DESIGN MANAGEMENT, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Disturbances in movement coordination are the least well understood but often the most debilitating with respect to functional recovery following stroke. These deficits in coordination are expressed in the form of abnormal muscle synergies and result in limited and stereotypic movement patterns that are functionally disabling. The result of these constraints i ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  9. A 3-D Robot Design to Overcome Arm Dysfunction in Stroke

    SBC: LAM DESIGN MANAGEMENT, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Disturbances in movement coordination are the least well understood but often the most debilitating with respect to functional recovery following stroke. These deficits in coordination are expressed in the form of abnormal muscle synergies and result in limited and stereotypic movement patterns that are functionally disabling. The result of these constraints i ...

    STTR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health
  10. Aerosolized Chemically Modified Tetracycline Nanoformulation for the Treatment of Acute Respiratory Distress Syndrome

    SBC: CMTX BIOTECH, INC.            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT CMTx Biotech is a drug development company working to rescue, develop and commercialize a proprietary clinical-stage drug candidate, incyclinide (CMT-3 / COL-3), for the treatment of sepsis patients at risk of acute respiratory distress syndrome (ARDS). According to the U.S. Centers for Disease Control (CDC), at least 1.7 million American adults develop sepsis annually, re ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government